by Oxford/AstraZeneca’s Covid-19 Nasal VaccineFailed early clinical trials, which will force researchers to rethink the design. Experts have previously touted the potential of a nasal vaccine for SARS-CoV-2, arguing that it could ward off SARS-CoV-2 virus particles before they have a chance to cause infection. But the Oxford/AstraZeneca nasal vaccine did not show the potential to ward off infection in Phase I clinical trials, with seven of 42 participants becoming infected after vaccination.research reportPublished in the journal eBioMedicine. The good news in clinical trials is that the vaccine is safe.
